Although current clinical and pathological indicators such as Gleason score (tumor grade), cancer stage, and prostate-specific antigen (PSA) level have been the most reliable prognostic factors, they do not accurately predict the progression risk of individual patients (Cooperberg et al., 2015; Leapman et al., 2018). The gene discussed is KLK3; the disease is cancer.